$105.26
1.81% today
Nasdaq, Jun 25, 03:45 pm CET
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Gilead Sciences Stock price

$107.20
-0.17 0.16% 1M
+13.25 14.10% 6M
+14.83 16.06% YTD
+36.47 51.56% 1Y
+44.12 69.94% 3Y
+31.27 41.18% 5Y
-14.81 12.14% 10Y
+96.76 927.07% 20Y
Nasdaq, Closing price Tue, Jun 24 2025
+1.01 0.95%
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Key metrics

Basic
Market capitalization
$133.3b
Enterprise Value
$150.4b
Net debt
$17.0b
Cash
$7.9b
Shares outstanding
1.2b
Valuation (TTM | estimate)
P/E
22.66 | 17.74
P/S
4.64 | 4.65
EV/Sales
5.23 | 5.24
EV/FCF
15.65
P/B
6.97
Dividends
DPS
$3.08
Yield 1Y | 5Y
2.87% | 4.04%
Growth 1Y | 5Y
2.67% | 4.10%
Payout 1Y | 3Y
810.53% | 105.63%
Increased
10 Years
Financials (TTM | estimate)
Revenue
$28.7b | $28.7b
EBITDA
$15.1b | $14.2b
EBIT
$11.0b
Net Income
$6.0b | $7.5b
Free Cash Flow
$9.6b
Growth (TTM | estimate)
Revenue
4.68% | -0.21%
EBITDA
17.67% | 4.35%
EBIT
8.48%
Net Income
1,132.44% | 1,467.63%
Free Cash Flow
21.62%
Margin (TTM | estimate)
Gross
78.29%
EBITDA
52.64% | 49.44%
EBIT
38.17%
Net
20.76% | 26.22%
Free Cash Flow
33.44%
Financial Health
Equity Ratio
32.77%
Return on Equity
2.48%
ROCE
24.88%
ROIC
22.21%
Debt/Equity
1.30
More
EPS
$4.73
FCF per Share
$7.72
Short interest
1.68%
Employees
17.60k
Rev per Employee
$1.63m
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Gilead Sciences forecast:

18x Buy
60%
12x Hold
40%

Analyst Opinions

30 Analysts have issued a Gilead Sciences forecast:

Buy
60%
Hold
40%

Financial data from Gilead Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
28,735 28,735
5% 5%
100%
- Direct Costs 6,239 6,239
1% 1%
22%
22,496 22,496
6% 6%
78%
- Selling and Administrative Expenses 5,857 5,857
6% 6%
20%
- Research and Development Expense 5,671 5,671
0% 0%
20%
15,126 15,126
18% 18%
53%
- Depreciation and Amortization 4,157 4,157
52% 52%
14%
EBIT (Operating Income) EBIT 10,969 10,969
8% 8%
38%
Net Profit 5,965 5,965
1,132% 1,132%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Positive
Reuters
about one hour ago
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
Neutral
Business Wire
about 3 hours ago
FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatme...
Positive
Seeking Alpha
one day ago
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered dividends. Both carry moat-worthy attributes and provide economically essential products and services that make them recession resilient.
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 17,600
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today